Sanofi S.A. (NASDAQ: SNY)

Q: What is Sanofi S.A.'s revenue?

Sanofi S.A. has annual revenue of approximately $46.0 billion.

Q: How many employees does Sanofi S.A. have?

Sanofi S.A. employs approximately 91,000 people.

Drug Manufacturers - General · Paris, France · Founded 2004

$130.0B

Market Cap

$46.0B

Revenue

91,000

Employees

$6.0B

Net Income

📊 Key Statistics for Sanofi S.A. (SNY)

Market capitalization: $130.0 billion
Annual revenue: $46.0 billion
Net income: $6.0 billion
Employees: 91,000
Sector: Healthcare
Headquarters: Paris, France
Founded: 2004

Source: Statvoo company profile for Sanofi S.A.. Browse all 500+ companies

📋 About Sanofi S.A.

Sanofi is a French pharmaceutical giant and one of the world's largest drugmakers, specializing in immunology, oncology, rare diseases, and vaccines. The company produces Dupixent (the blockbuster eczema/asthma drug), flu vaccines for hundreds of millions, and treatments for rare genetic diseases.

sanofi.com analysis · Visit website →

💰 How Sanofi S.A. Makes Money

Develop, manufacture, and sell prescription drugs and vaccines globally. Dupixent alone generates over $13 billion annually. The vaccine division (Sanofi Pasteur) is the world's largest, producing over 1 billion doses annually. Revenue is split roughly 70% pharmaceuticals, 30% vaccines and consumer healthcare.

📜 Key Milestones

Sanofi's history traces back to 1973 when French oil company Elf Aquitaine entered pharmaceuticals. Decades of mergers created the current entity — Sanofi-Synthélabo (1999), then the Aventis acquisition (2004). The company spun off its consumer health division (Opella) in 2024 to focus on innovative medicines.

📊 Financial Overview

Market Capitalization	$130.0B
Annual Revenue	$46.0B
Net Income	$6.0B
Profit Margin	13%
Revenue per Employee	$505495K
Stock Exchange	NASDAQ
Ticker Symbol	SNY

Financial data is approximate and based on most recent annual filings.

💡 Did You Know?

Dupixent is one of the most successful drug launches in pharmaceutical history — from zero to $13+ billion in revenue in 7 years. Sanofi produces more flu vaccine doses than any other company. The company's rare disease portfolio (Fabry, Gaucher, Pompe diseases) serves patients with no other treatment options.

📝 Analyst Take

Sanofi's transformation from a diversified pharma conglomerate to a focused immunology/vaccine company is working. Dupixent's growth trajectory is exceptional with label expansions into new indications. The vaccine business provides stability. The risk is Dupixent concentration — it's becoming too large a share of total revenue.

❓ Frequently Asked Questions